Personalized rTMS therapy to improve walking in Parkinson's patients
Official title: Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease
Run by Samsung Medical Center · NCT06350617 · Data updated 2026-11-12
This study is testing whether personalized brain stimulation can help improve walking in people with Parkinson's disease better than standard treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | February 20, 2024 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | April 28, 2026 |
| Trial ID | NCT06350617 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 50 and older with Parkinson's disease who can walk without assistance and are in stages 2 to 4 of the Modified Hoehn and Yahr scale.
✕Probably not a fit
Patients with significant cognitive impairment or other neurological conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of personalized repetitive transcranial magnetic stimulation (rTMS) protocols tailored to the functional reserve of patients with Parkinson's disease. By categorizing patients based on their motor and cognitive functional reserves, the study aims to compare the efficacy of these personalized protocols against conventional high-frequency rTMS applied to the primary motor cortex. The approach seeks to enhance motor function recovery by addressing the unique needs of each patient rather than using a one-size-fits-all method. Participants will be randomly assigned to different treatment groups to evaluate the outcomes of this tailored therapy.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatments for improving mobility in patients with Parkinson's disease.
How similar studies have gone: While traditional rTMS has been widely studied, this personalized approach based on functional reserve is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria, 2. Modified Hoehn and Yahr (H\&Y) scale, stage 2\~4, 3. patients who can walk on flat surfaces without the need for a gait aid, 4. aged ≥50 years old, 5. patients willing to sign the informed consent. Exclusion Criteria: 1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy, 2. those with cognitive impairment, confirmed through the Montreal Cognitive Assessment (MoCA) test as follows: \< 7 points: Illiterate \< 13 points: Education duration 0.5-3 years \< 16 points: Education duration 4-6 years \< 19 points: Education duration 7-9 years \< 20 points: Education duration 10 years or more 3. those with coexisting neurological conditions, such as spinal cord injury or Stroke, 4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia, 5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate. 6. those having contraindications to conduct an MRI study, 7. those who are pregnant or lactating, 8. patients who have refused to participate in this study.
Where it's running
-
Samsung Medical Center
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Won Hyuk Chang, PhD — Samsung Medical Center
- Study coordinator: Won Hyuk Chang, PhD
- Email: wh.chang@samsung.com
- Phone: +82-2-3410-6068
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MAO-B PET/CT imaging in Parkinson’s-related diseases
This study tests whether 18F-FPyCO/SMBT-1 PET/CT can help diagnose Parkinson’s-related conditions by measuring lesion uptake in patients with PD, PD dementia, or parkinsonism.
-
Sleep and DBS: Testing Deep Brain Stimulation Effects on Sleep in Parkinson’s
This study tests how turning the Deep Brain Stimulation device on or off affects sleep quality in people with Parkinson’s who already have a DBS implant.
-
Detecting phosphorylated alpha-synuclein in colon tissue to help diagnose Parkinson's
This study will test whether routine colonoscopy tissue samples from adults with Parkinson's show phosphorylated alpha-synuclein, a protein linked to the disease.
-
tDCS to improve swallowing in Parkinson's disease
This study tests whether adding transcranial direct current stimulation (tDCS) to standard swallowing therapy helps people with Parkinson's disease who have dysphagia.
-
Investigating how deep brain stimulation affects sleep in Parkinson's disease
This study is testing how deep brain stimulation affects sleep in people with Parkinson's disease to see if it can help improve their sleep quality.
-
Improving balance in Parkinson's disease using blood flow restriction
This study is testing whether using blood flow restriction during balance exercises can help people with Parkinson's disease improve their walking, balance, and endurance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.